HC Wainwright restated their buy rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.64) EPS, FY2024 earnings at ($2.34) EPS, FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($2.43) EPS.
Several other brokerages also recently weighed in on OLMA. JPMorgan Chase & Co. reduced their target price on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $27.00.
Get Our Latest Stock Analysis on OLMA
Olema Pharmaceuticals Stock Performance
Institutional Investors Weigh In On Olema Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OLMA. Conway Capital Management Inc. purchased a new position in shares of Olema Pharmaceuticals during the third quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. grew its stake in Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock worth $132,000 after purchasing an additional 4,442 shares in the last quarter. Portland Investment Counsel Inc. purchased a new position in Olema Pharmaceuticals during the 3rd quarter worth $143,000. Cubist Systematic Strategies LLC bought a new stake in Olema Pharmaceuticals during the 2nd quarter valued at $145,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth $156,000. Institutional investors own 91.78% of the company’s stock.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
- Five stocks we like better than Olema Pharmaceuticals
- What is Forex and How Does it Work?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Pros And Cons Of Monthly Dividend Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Top Biotech Stocks: Exploring Innovation Opportunities
- Time to Load Up on Home Builders?
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.